Study drug AUM001 with immunotherapy or chemotherapy for metastatic colon cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This Phase 2 trial tests AUM001 (a targeted drug) combined with either pembrolizumab (an immunotherapy) or irinotecan (a chemotherapy) in people with metastatic colorectal cancer. It aims to shrink tumors and improve outcomes when standard treatments have already been tried.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re 18 or older and can sign informed consent.
- You have colorectal cancer that is locally advanced or has spread to other parts of the body (metastatic), confirmed by lab tests.
- You’ve had more than 2 prior treatments for your colorectal cancer (and the prior treatment history must fit the study rules).
- You can provide a tumor tissue sample (existing sample or a new biopsy) from a spot that hasn’t been previously irradiated.
- Your scans show measurable disease, your activity level is good (ECOG 0–1), and you’re expected to live at least 3 months.
- You must have adequate blood/organ function and be able to take oral medication.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests an individualized treatment chosen from your tumor’s lab testing (genetic and RNA profile plus a drug-sensitivity test from your tumor cells). It may help by matching you to targeted anti-cancer drugs that are most likely to work for your specific cancer.
This Phase 2 trial tests a chemotherapy combination (liposomal irinotecan), along with TAS-102 and bevacizumab, in people with metastatic colon cancer. It may help if your tumor has mismatch repair–proficient features and you’ve already tried standard colon cancer drugs.
This Phase 2 study tests adding anlotinib and penpulimab to irinotecan for colorectal cancer that has come back or spread after earlier chemotherapy. It may help shrink tumors and control the disease when standard first-line treatment no longer works.
This Phase 1 study tests targeted cancer treatments in people with metastatic colorectal cancer, using genetic “biomarker” results to match you to the right treatment group. It focuses first on safety, and also looks for early signs the treatment may work in specific tumor subgroups.
This trial tests a combination of a targeted therapy pill (TKI) and an immunotherapy (PD-1 inhibitor) for people with advanced colorectal cancer that has stopped responding to standard treatments. It uses a blood test to tailor the treatment, aiming to be more effective with fewer side effects.
This trial tests a new drug combination (ABT-301, tislelizumab, and bevacizumab) for people with a specific type of advanced colorectal cancer that has not responded to at least two prior treatments. It aims to see if this combination can help shrink tumors or slow the disease.
Hear when a new Metastatic Colorectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.